One in 10 adults in Korea used or was prescribed obesity drugs such as Wegovy and Mounjaro in the past year, with younger generations reporting higher usage and one-third of respondents saying they would use such drugs in the future. According to the “2026 Korea Wellness Report” released Sunday by KB Financial Group, 10.3 percent of the 2,000 men and women aged 25 to 69 who were surveyed in July and August said they used or were prescribed GLP-1 obesity drugs in the past year. The drugs mimic hormones that regulate appetite and blood sugar to aid weight loss. By generation, Generation Z, born after 1995, had the highest usage rate at 16.5 percent, followed by millennials at 14.2 percent, Generation X at 7.7 percent and baby boomers at 2.9 percent. Usage was higher among men at 11.6 percent than women at 9 percent, but women were more aware of the drugs at 83.1 percent than men at 73 percent. Asked about future use, 33.9 percent of respondents said they would use obesity drugs if circumstances allowed, with the share rising to 39.7 percent among Gen Z, who cited “appearance and bod